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Abstract
Background—Epidemiologic studies of prescription medications increasingly rely on large
administrative healthcare databases. These data do not capture patients’ use of medication
samples. This could potentially bias studies of short-term effects where date of initiation may be
inaccurate.
Objectives—Assess the extent of sample use among patients initiating statin therapy.
Research Design—Retrospective cohort of patients who filled a first prescription for a statin
after at least 6 months of statin-free period in 2007-2010. LDL values obtained within the 15 days
preceding the first prescription were analyzed using a 2-component Gaussian mixture model to
look for evidence of prior treatment.
Subjects—A total of 26,033 statin initiators with at least 1 LDL lab within the 15 days preceding
the prescription fill.
Measures—Estimators for the proportion of patients filling a new prescription already on
treatment.
Results—Among 9,256 patients filling a branded statin, LDL distribution was bimodal,
consisting of 2 Gaussian distributions: one, which made up 13.4% of the total population, had
much lower LDL values (mean=71.8 mg/dL) compared to the second (mean=148.0 mg/dL),
suggesting drug use prior to first dispensed prescription. Among 16,777 patients filling a generic
statin, LDL levels were substantially higher with no evidence of bimodality that would suggest
prior sample use.
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Conclusion—These results provide indirect evidence that the initial period of branded
medication use may often be missed when using pharmacy claims data to define drug initiation.
Further research is needed to examine approaches to better identify incident medication use when
assessing short-term effects.
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INTRODUCTION
Large healthcare claims databases are widely used in pharmaceutical outcome research, drug
safety surveillance, and healthcare quality improvement programs.1-5 These databases
capture information on dispensed medications through claims sent by the pharmacy to the
pharmacy benefit manager. Because this information on medication exposure is collected
prospectively, it is not prone to recall or interview bias. However, concerns have been raised
about the data incompleteness.6, 7 A recent US study of patients being anticoagulated for
atrial fibrillation found that approximately 10% of patients receiving regular monitoring to
manage medications had no evidence of medication use in the pharmacy claims.8
Incomplete capture of prescription medications may result when patients use drugs during
hospital stay, 6 use a spouse’s pharmacy benefit, or pay cash for prescriptions.7 No record of
these drugs will exist in the insurance pharmacy claims data. Another contributing factor to
misclassified drug exposure results from the use of free samples. In 2010, the
pharmaceutical industry provided medication samples worth $14 billion to physicians.9 A
survey conducted in 2006 found that 58% of physicians frequently give samples to
patients.10 Free samples are given to find the optimal dose or test for efficacy and
tolerability of medication before a patient starts on a long-term treatment.11-13
Missing information on prescription medication use may adversely affect research and
quality improvement activities that rely on these data.14-17 To understand the potential
impact of missing data due to sampling on these activities, we sought to estimate the
prevalence of free sample use among statin initiators in a large healthcare database. We used
a new design that considers low-density lipoprotein (LDL) test results before the first
prescription claim to assess the probability that patients filling a prescription may already be
on treatment. Since guidelines recommend monitoring statin therapy by checking LDL
levels shortly after the start of treatment,18 we assumed that many physicians would provide
a first course of treatment using samples and would monitor these laboratory values before
writing a long-term prescription. We used the distribution of LDL just before the first
dispensed prescription to estimate the proportion of patients receiving a first course of
treatment via samples.
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Data sources and study population
We identified a cohort of patients initiating statin treatment using the Truven Health
Analytics MarketScan® Commercial Insurance Claims and Encounters and Laboratory
Results Databases for the years 2007-2010. These databases represent the medical
experience of insured employees and dependents in the US with primary coverage through
privately insured fee-for-service, point-of-service, or capitated health plans. All enrollment
records and inpatient, outpatient, ancillary, and pharmaceutical drug claims are collected for
approximately 20 million people annually from over 100 nationwide insurers. Laboratory
results are available on patients who have the test ordered and the sample sent to a specific
national testing company. Personal identifiers are removed from all analytical data files. The
UNC Institutional Review Board approved this study.
Using these data and a new-user design, we identified a retrospective cohort of patients who
were statin new users between July 1st, 2007 and July 1st, 2010. New users of statins were
defined as patients who had a prescription claim for any statin formulation following 6
statin-free months of observed plan enrollment, and the index date was the first statin
prescription fill date. To ensure patients were utilizing pharmacy benefits, at least 1
prescription claim was required on any non-statin medication during the 6-month period
preceding the index date. The cohort consisted of new users at least 40 years old at the index
date who had at least 1 LDL lab result between 0 and 300 milligrams per deciliter (mg/dL)
during the 6 statin-free months. Patients who had their last LDL lab obtained more than 15
days prior to the index date were excluded. The study design and cohort creation process are
illustrated in Figure 1 and Figure 2.
We created a number of covariates for demographic information, clinical conditions and co-
medications based on claims occurring in the 6-month period preceding the index date.
Conditions were derived using definitions consisting of diagnoses with relevant
International Classification of Diseases, Ninth Revision, Clinical Modification codes,
procedures with Current Procedural Terminology codes, and medication usage with National
Drug Codes, merged with REDBOOK supplement. The values of LDL labs were identified
by the Logical Observation Identifiers Names and Codes (LOINC®) in the Laboratory
Results Database (LOINC: 13457-7).
Statins and LDL
Statins, the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are used to lower
LDL levels to prevent cardiovascular disease events.19, 20 While the 2013 guidelines move
away from a specific LDL value, 21 according to guidelines in effect during the study
period, statin treatment decisions were largely determined by LDL level, with less than 100
mg/dL deemed optimal, and lipid panels were closely monitored before and during
treatment.18, 22 Statins are highly effective at lowering LDL levels with 90% of therapeutic
response apparent within 2 weeks.23 Systematic reviews of several placebo-controlled trials
showed that LDL reduction from baseline ranged from 18% to 58% among participants
receiving statins.18, 24-25 A randomized, parallel-group, comparator-controlled trial also
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showed a reduction of 20-55% by the end of 6 weeks.26 Branded statins are one of the most
frequently reported free drug samples,27 and samples are generally used to provide a first
course of therapy. We classified index statin drugs as branded or generic based on the drug’s
patent status at the time of prescription fill.
Statistical analyses
Because statins are highly effective at lowering LDL levels, patients on treatment will have
a different distribution of LDL compared to those not on treatment. If patients filling a first
prescription for a statin are a mix of patients already being treated (through the use of
samples) and newly treated patients, the distribution of LDL prior to first fill will follow a
mixture distribution.28
Based on the observation of the LDL distributions in Figure 3 and Figure 4 and its biological
plausibility, we modeled the distribution of LDL prior to first fill, LDL1 using a 2-
component Gaussian mixture model.29 Given only observations on the pooled population
with no sub-population identity information, finite mixture models are a useful way to
model unobserved heterogeneity and make statistical inferences about the properties of the
sub-populations. The areas of application of finite mixture models, also known as latent
class models and unsupervised learning models range from epidemiology,30 genetics,31
medicine32 to economics33 and marketing.34 The 2-component Gaussian mixture model
provided an estimate for the parameters of the 2 distributions via maximum likelihood
estimation using EM algorithms. The 2 distributions are reported as D (mean μ, standard
deviation σ), where D1 refers to the distribution with the lower mean and D2 corresponds to
the distribution with the higher mean. The mixing proportion parameter λ from the mixture
model provides an estimate of the percentage of patients already on treatment. The
difference in means between the 2 distributions provides an estimate of the treatment effect,
which is already approximately known from trials, and permits an assessment of the model’s
plausibility. Since free samples of branded statins are frequently distributed27 while samples
of generic statins are rarely offered,35 analyses were performed in branded and generic statin
users separately. Descriptive statistics were calculated and assessed for clinical and
demographic covariates.
To further confirm that there were prevalent users mixed in the identified new user cohort,
we compared the distributions of LDL1 to LDL2, an older LDL performed before LDL1, in
patients with at least 2 sequential LDL labs in the 6 statin-free months preceding the index
date. In these patients, we expected that the first LDL, LDL2 would motivate the start of
treatment (that may have been initiated through samples), and the second LDL, LDL1 would
be ordered to check the effectiveness of the first course of treatment on LDL levels. The
older LDL2 could then serve as a negative control, an indicator for the absence of
confounding. Finite mixture model analyses described above were performed in branded and
generic statin users separately.
To assess the robustness of the results and the possibility that a mixture distribution of LDL
was caused by other reasons, sensitivity analyses were conducted by restricting the analyses
to cohorts of patients without prevalent non-statin lipid-lowering medications, recent
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hospitalization or emergency room visits, or specific indications for statins including history
of diabetes, stroke, stenting or stress test, separately.
Descriptive statistics were calculated using SAS version 9.2 (SAS Institute, Cary, North
Carolina). All mixture model analyses were performed using R statistical software.
RESULTS
Between July 1st, 2007 and July 1st, 2010, we identified 26,033 continuously-enrolled
patients with pharmacy insurance benefits having a prescription fill for statins after a 6-
month statin-free period and at least an LDL laboratory value between 0 and 300 mg/dL
with the lab done within 15 days prior to the index date. Among them (Table 1), 35.6%
initiated on a branded statin, and 54.2% were female. The age at fill date ranged from 40 to
96 years old and averaged around 53 years in both user groups. The distribution of clinical
conditions including coronary syndromes, kidney diseases, and some metabolic syndromes
were similar in both user groups of generic and branded statins. People who had a stress test,
hyperlipidemia diagnoses or use of non-statin lipid-lowering co-medications within the last
6 months were more likely to initiate a branded statin.
The distribution of LDL1, the last LDL just before the first dispensed statin prescription, is
presented in Figure 3. The distributions are reported as D (mean μ, standard deviation σ),
where D stands for distribution. Among all 26,033 patients with at least 1 LDL result
available, the LDL level in the branded drug users had a bimodal distribution, corresponding
to a mixture of 2 normal distributions, D1 (71.8 mg/dL, 20.7 mg/dL) and D2 (148.0 mg/dL,
36.8 mg/dL). The percentage of patients who had free statin samples was estimated to be
13.4% in those filling a branded drug prescription. In comparison, the LDL level in the
generic drug users was estimated to be from a more homogeneous population.
To further examine if the date of drug initiation was misclassified in some patients having
utilized free drug samples, we compared the distributions of 2 sequential LDL labs in both
branded and generic drug user groups and presented the results in Figure 4. In this more
restrictive cohort, 5,698 patients had at least 2 LDL lab results available before filling a
statin prescription. The median time between the 2 LDL labs was 99 days. Similarly to
patients with at least 1 LDL lab result, the distribution of LDL1 in branded drug user group
was estimated to be a mixture of 2 normal distributions: D1 (75.4 mg/dL, 18.6 mg/dL) and
D2 (136.8 mg/dL, 37.0 mg/dL) while that of LDL1 in generic users was more homogeneous.
As expected, the distribution of LDL2, the older LDL lab performed before LDL1 were
shown to be from homogeneous distributions for both branded and generic drug users.
Among these patients initiating a branded drug, 25.6% of them were estimated to have had
free drug sample exposure.
Similar results were observed when we conducted sensitivity analyses in patients with no
recent hospitalization or emergency room visits, no specific indications for statins distinct
from elevated LDL levels, or no use of non-statin lipid-lowering medications separately. In
all cohorts, the LDL distributions were more homogenous in generic statin users, while there
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was evident bimodality in the LDL distributions in branded statin users with estimates
consistent with those of primary analyses.
DISCUSSION
In this study of patients starting statin lipid-lowering treatment, we found strong evidence of
prior medication use among patients filling a first prescription. Among patients filling a first
prescription for a branded statin, we observed a bimodal distribution of LDL lab values
recorded just before the first prescription fill, with many LDL levels well below treatment
targets for statin therapy. Using a 2-component Gaussian mixture model, we estimated that
about 1 in 7 of those patients filling a first prescription for a branded statin had evidence of
first course of treatment using samples prior to first prescription claim. Among patients
filling a prescription for a generic statin, the LDL distribution had no evidence of bimodality
that would suggest prior treatment. We think that sample use is the most likely explanation
for these findings, since samples would be associated with the use of branded medications,
but not generic.
There are other potential reasons why earlier treatments may not be captured in the
pharmacy claims. For example, treatment will not be captured if patients use supplements or
over-the-counter medications, pay cash for prescriptions, use a spouse’s pharmacy benefit, 7
or use drugs during hospital stay.6 However, the likelihood of these occurrences should be
similar, if not higher among users of generic compared to branded medications. Sensitivity
analyses with patients who had no recent hospital stay or emergency room visit also showed
no change in the results.
Besides treatment through samples, we considered other possible explanations for the
bimodal distribution of LDL before the first prescription fill of a branded statin. For
example, therapeutic lifestyle changes (TLC) through dietary therapy, weight management
and exercise are normally initiated before or along drug therapy and could also contribute to
the decrease in LDL level with a mean reduction of 11%.18 Due to its essential role in
cholesterol management and common practice as the initial step, however, the effect of TLC
on LDL level should be similar in both users of generic and branded medications. The
bimodal distribution could also be a result of different populations of patients having
different LDL targets depending on their risk profiles for cardiovascular diseases.19
However, when these patients with specific indications distinct from elevated LDL
including history of diabetes, stroke, stenting or stress test were excluded, results similar to
the original cohort were observed with differential presence of bimodality in the branded
medication users, suggesting sample use was the most plausible explanation.
Patients initiating statin therapy for lipid management are recommended to have LDL levels
evaluated every 6 to 8 weeks until the goal level is achieved.18 In patients with 2 labs
available prior to the first prescription fill, we expected that the first LDL would motivate
the start of treatment (that may have been initiated through samples), and the second LDL
would be ordered to check the effectiveness of the first course of treatment on LDL levels.
Our analysis supports this hypothesis. Among patients who had at least 2 sequential LDL
labs values during the baseline period, the last recorded LDL exhibited strong evidence of
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bimodality among branded medication users; whereas the first LDL observed exhibited no
evidence of bimodality and had a higher mean that was consistent with LDLs from an
untreated hyperlipidemic population.25 This analysis suggested that pre-treatment pattern of
testing can be used to identify patients starting treatment on samples.
These findings in our study provided evidence that the date of drug initiation can be
misclassified in some patients due to free sample drug utilization when using pharmacy
claims data to ascertain exposure status. The result was most pronounced in people filling a
branded statin. It is possible for patients filling a prescription for a generic drug to receive
samples but the likelihood is low.11 It is possible, however, that some patients initiated on a
branded drug sample decided to switch to a generic drug. Perhaps because the effect of the
drug was not satisfactory, the patients were intolerant to side effects, or they preferred to
reduce the co-pay. If this happens at all, it seems to be rare, however, and we were not able
to detect the mixture in our analysis. Because of the requirement of having at least 1 statin
prescription fill, our analysis did not include patients who initiated treatment via consecutive
free samples and never received a prescription for a statin. The presence of these patients
could affect studies including non-users.
Our study has important implication for pharmacoepidemiologic research and quality of care
research using US healthcare claims databases. In particular, events that occur while a
patient is taking samples may not be appropriately linked to the medication. Since samples
are often used at the start of treatment,11-14 early events caused by the medication could be
missed. This could cause medications that are provided as samples to appear safer with
respect to the short-term risk of adverse events. This will need to be taken into consideration
by the various drug safety surveillance activities that rely on these data. In studies where a
drug that is often provided as samples is being compared to a drug that is not, the drug
provided via samples through early events would be missed. The magnitude of bias caused
by this exposure misclassification will depend on the extent of free sample use and the
incidence of early adverse events in the exposure groups.14, 36
Misclassification of exposure may be particularly problematic for case-only designs,
including self-controlled case series, case-crossover and sequence symmetry analyses, since
these designs are more susceptible to bias due to exposure measurement error than
conventional studies.37 In studies that compare branded to generic medications, the apparent
new users of branded medications may consist of many patients who have already been
receiving treatment through the use of samples. These are patients who are more likely to be
tolerant of treatment, to perceive a benefit of treatment, and also more likely to be adherent
to therapy.38, 39 This could lead to systematic differences between the exposure groups.
When patients start treatment on samples, cumulative exposure will also be under-
ascertained among new users of branded medications. This could lead to slightly
exaggerated estimates of both the benefits and risks associated with short-term exposures
but it is likely to be small for longer-term exposures. For pharmacoepidemiologic research
that attempts to control confounding by using laboratory values, care must be taken to make
sure that the laboratory values are assessed prior to the true start of treatment. Controlling
for post-treatment variables can increase rather than decrease bias in point estimates to the
extent that they serve as causal intermediates.40
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We have identified a potential issue for exposure misclassification due to missing
information on sample use when conducting research using pharmacy claims data, but we do
not yet have solutions to address it. This is a complex issue and deserves additional research
to examine approaches that can be used to better identify true incident medication use. Our
research suggests that looking at timing of tests and physician visits prior to medication
initiation may be useful for identifying patients who have likely been receiving samples. For
example, for drug therapy such as statin therapy that requires follow-up testing, it appears
that restricting the analysis to patients who have a single LDL immediately prior to
treatment may substantially reduce the percentage of patients starting treatment on samples.
For medications that do not require immediate follow-up with a physician for dose titration,
simply requiring a physician visit shortly prior to the first pharmacy claim may exclude
patients who start treatment using samples. Another possible approach is to start follow up
after a fix period of time following the second prescription fill for all comparison groups.
This approach, however, may not be optimal in situations where very early events are of
interest, due to the depletion of susceptibles.
Our study has several important limitations. First, our analysis focused only on patients with
private insurance in the US and therefore may not generalize to other populations, such as
those with Medicaid or Medicare. Second, our results will not necessarily generalize to other
medications, other study periods or research databases in other countries. Due to different
patent status, promotional expenditures, pharmaceutical policies and regulations, the amount
of missing data due to free drug sample utilization will change. It may be important for
researchers to take into account the prevalence of sample use in the time period in which a
study is done. Moreover, LDL laboratory results were only available if the blood sample
was sent to a specific national testing company. If samples were tested in the clinic or sent to
a different testing company, the LDL results would be missing. However, the average values
of LDL measurements in these data were close to their population means, as estimated from
a nationally-representative data from the National Health and Nutrition Examination
Survey.41 Therefore, we think missing LDL results are not likely to have an important effect
on generalizability.
In conclusion, we found evidence that a substantial portion of patients filling branded
prescriptions for statin medications were likely to have received drug samples previously
and that in these patients the start date of therapy based on pharmacy-dispensing data would
be incorrect. This finding has important implication for pharmacoepidemiology and quality
of care research using US healthcare databases. Caution must be exercised when
ascertaining start date for drug exposure using pharmacy-dispensing data from healthcare
claims databases, especially for short-term effects when branded medications that are
available as samples are compared to generic medications. Further research is needed to
identify study designs that minimize exposure misclassification in comparative new-user
studies of medications that many patients may start through the use of free samples.
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Schematic of the statin user cohort study design. Not all patients had LDL2 in the primary
cohort.
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Flow diagram of the cohort creation process: new users of statins, ≥40 years of age, United
States, 2007-2010
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The distribution of last LDL before first statin prescription fill in patients with at least 1
LDL lab prior to first statin prescription fill.
((a) Results from mixture model analysis: λ =proportion, μ =mean (mg/dL), σ =standard
deviation (mg/dL), D =distribution;
(b) Left panel: Patients filling a prescription for branded drug; Right panel: patients filling a
prescription for generic drug)
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The distributions of 2 sequential LDLs before first statin prescription fill in patients with 2
or more LDL labs prior to first statin prescription fill.
((a) Results from mixture model analysis: λ =proportion, μ =mean (mg/dL), σ =standard
deviation (mg/dL), D =distribution;
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(b) (Top panels: the last LDL, LDL1; Bottom panels: the older LDL, LDL2; Left panels:
Patients filling a prescription for branded drug; Right panels: patients filling a prescription
for generic drug)
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Table 1
Demographic and Clinical Characteristics of the New Users of Statins Who Initiated Between July 1, 2007










% 64.4 35.6 100.0
Age, Mean (SD), year 53.9 (7.9) 52.7 (6.7) 53.4 (7.5)
Gender
Female 55.3 52.3 54.2
Comorbidities
Chronic Heart Failure 1.0 1.0 1.0
Stroke 2.7 2.6 2.7
Hyperlipidemia 61.3 70.9 64.7
Hypertension 44.1 45.9 44.7
Type 2 Diabetes 25.1 23.3 24.4
Coronary Syndrome
Atrial Fibrillation 1.4 1.4 1.4
Unstable Angina prior to the last 3 weeks 0.3 0.5 0.4
Unstable Angina in the last 3 weeks 0.4 0.5 0.4
Myocardial Infarction in the last 3 weeks 0.4 0.2 0.3
Kidney Disease
Acute Kidney Injury 0.2 0.2 0.2
Chronic Kidney Diseases 1.5 1.7 1.6
Dialysis 0.0 0.0 0.0
End Stage Renal Disease 0.1 0.1 0.1
Procedures
Stenting 0.5 0.7 0.6
Stress Test 4.6 7.4 5.6
Emergency room visit in last 2 weeks 2.9 2.1 2.7
Hospitalization in last 2 weeks 1.4 0.7 1.1
Co-medications
Ezetimibe 1.5 2.6 1.9
Fibrates 4.4 5.3 4.7
Nicotinic acid 0.7 1.6 1.0
Note: The percentages presented are column percentages. SD = standard deviation
a
During the study period, the generic drugs initiated were Lovastatin, Pravastatin Sodium and Simvastatin.
b
During the study period, the branded drugs initiated were Advicor (Lovastatin/Niacin), Caduet (Amlodipine Besylate/Atorvastatin Calcium),
Crestor (Rosuvastatin Calcium), Lipitor (Atorvastatin Calcium), Lescol (Fluvastatin Sodium), Simcor (Simvastatin/Niacin) and Vytorin
(Ezetimibe/Simvastatin).
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